European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading

MT Newswires Live06-12

European equities traded in the US as American depositary receipts were moving sharply higher late Wednesday morning, rising 1.59% to 1,445.87 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by software firm SAP (SAP) and biopharmaceutical firm Grifols (GRFS), which rose 3.9% and 3.7%, respectively. Semiconductor company Sequans Communications (SQNS) and kidney dialysis company Fresenius Medical Care (FMS) added 3.2% and 2.8%, respectively.

The decliners from continental Europe were led by biopharmaceutical firm Genfit (GNFT) and pharmaceutical firm Ascendis Pharma (ASND), which both retreated 4.7%. Biopharmaceutical company Cellectis (CLLS) was also down 2.8% and furniture maker Natuzzi (NTZ) declined 2.2%.

From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Mereo BioPharma Group (MREO), which climbed 12% and 9.7% respectively. They were followed by biopharmaceutical companies Verona Pharma (VRNA) and Amarin Corporation (AMRN), which were up 6.9% and 2.8% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Akari Therapeutics (AKTX), which fell 6.1%, while biotech firm Autolus Therapeutics (AUTL) declined 4.5%. They were followed by pharmaceutical company Silence Therapeutics (SLN) and telecommunications operator Vodafone Group (VOD), which were down 1.4% and 0.3% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment